JP2009504614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504614A5 JP2009504614A5 JP2008525578A JP2008525578A JP2009504614A5 JP 2009504614 A5 JP2009504614 A5 JP 2009504614A5 JP 2008525578 A JP2008525578 A JP 2008525578A JP 2008525578 A JP2008525578 A JP 2008525578A JP 2009504614 A5 JP2009504614 A5 JP 2009504614A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CBN(*)C(c1c(*)c(*)c(*)c(C(NC(*)C(*)(*)NC(*)C(N(*)*)=O)=O)c1*)=O Chemical compound CBN(*)C(c1c(*)c(*)c(*)c(C(NC(*)C(*)(*)NC(*)C(N(*)*)=O)=O)c1*)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05017475 | 2005-08-11 | ||
| PCT/EP2006/065157 WO2007017511A2 (de) | 2005-08-11 | 2006-08-08 | Verbindungen zur behandlung der alzheimer erkrankung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504614A JP2009504614A (ja) | 2009-02-05 |
| JP2009504614A5 true JP2009504614A5 (OSRAM) | 2009-09-24 |
Family
ID=37719340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525578A Pending JP2009504614A (ja) | 2005-08-11 | 2006-08-08 | アルツハイマー病の治療用化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100144681A1 (OSRAM) |
| EP (1) | EP1919861A2 (OSRAM) |
| JP (1) | JP2009504614A (OSRAM) |
| CA (1) | CA2618481A1 (OSRAM) |
| WO (1) | WO2007017511A2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2618474A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for treating alzheimer's disease |
| CN101981003B (zh) | 2008-02-29 | 2014-07-02 | 伊沃泰克股份公司 | 酰胺化合物、组合物及其应用 |
| JP5608655B2 (ja) | 2008-09-18 | 2014-10-15 | エヴォテック アーゲー | Ｐ２ｘ３受容体活性のモジュレーター |
| US9000047B2 (en) | 2010-05-24 | 2015-04-07 | Farmalider, S.A. | Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses |
| US20120053200A1 (en) * | 2010-09-01 | 2012-03-01 | Harald Mauser | Bace 2 inhibitors |
| US9394236B2 (en) | 2014-02-03 | 2016-07-19 | Quadriga Biosciences, Inc. | β-substituted γ-amino acids and analogs as chemotherapeutic agents |
| WO2015117147A1 (en) | 2014-02-03 | 2015-08-06 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| CA2994404C (en) | 2015-08-03 | 2020-12-08 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991019810A1 (en) * | 1990-06-15 | 1991-12-26 | California Biotechnology Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| CA2372251A1 (en) * | 1991-01-21 | 1992-08-06 | Michael John Mullan | Test and model for alzheimer's disease |
| JPH07506720A (ja) * | 1992-01-07 | 1995-07-27 | アテナ ニューロサイエンシーズ， インコーポレイテッド | アルツハイマー病のトランスジェニック動物モデル |
| US5604102A (en) * | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| JPH09507746A (ja) * | 1993-10-27 | 1997-08-12 | アテナ ニューロサイエンシズ，インコーポレイティド | Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物 |
| US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| AU6383396A (en) * | 1995-06-07 | 1996-12-30 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
| US5744346A (en) * | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| BR0209973A (pt) * | 2001-05-25 | 2004-04-06 | Warner Lambert Co | Composição farmacêutica lìquida |
| EP1453516A2 (de) * | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| RS50504A (sr) * | 2001-11-08 | 2007-04-10 | Elan Pharmaceuticals Inc., | Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana |
| CH698246B1 (de) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
| JP2005534614A (ja) * | 2002-01-04 | 2005-11-17 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病治療のための置換アミノカルボキサミド |
| NZ538625A (en) * | 2002-09-06 | 2008-05-30 | Pharmacia & Upjohn Co Llc | 1,3-Diamino-2-hydroxypropane prodrug derivatives |
| EP1562897B1 (en) * | 2002-11-12 | 2009-09-16 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
| US20050090449A1 (en) * | 2003-05-13 | 2005-04-28 | Boehringer Ingelheim International Gmbh | Novel statine derivatives for the treatment of Alzheimer's disease |
| JP2007516207A (ja) * | 2003-06-30 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤 |
| WO2005065195A2 (en) * | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| CA2567223A1 (en) * | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Treatment of diseases associated with altered level of amyloid beta peptides |
| WO2005113582A1 (en) * | 2004-05-22 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease |
| WO2006050861A2 (en) * | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
| WO2006050862A1 (en) * | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
| WO2006103038A1 (en) * | 2005-03-30 | 2006-10-05 | Boehringer Ingelheim International Gmbh | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
| CA2617294A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
| US20090042867A1 (en) * | 2005-08-11 | 2009-02-12 | Klaus Fuchs | Compounds for the treatment of alzheimer's disease |
| CA2618474A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for treating alzheimer's disease |
| JP2009504611A (ja) * | 2005-08-11 | 2009-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルツハイマー病の治療用β−セクレターゼインヒビター |
-
2006
- 2006-08-08 JP JP2008525578A patent/JP2009504614A/ja active Pending
- 2006-08-08 WO PCT/EP2006/065157 patent/WO2007017511A2/de not_active Ceased
- 2006-08-08 CA CA002618481A patent/CA2618481A1/en not_active Abandoned
- 2006-08-08 EP EP06792737A patent/EP1919861A2/de not_active Withdrawn
- 2006-08-08 US US12/063,356 patent/US20100144681A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014366361B2 (en) | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators | |
| JP2020523388A5 (OSRAM) | ||
| AR062299A1 (es) | Derivados de bencimidazol | |
| CA2445515A1 (en) | Transcription factor modulating compounds and methods of use thereof | |
| CY1113067T1 (el) | Χρηση εκκριταγωγων αυξητικης ορμονης για τη διεγερση της κινητικοτητας του γαστρεντερικου συστηματος | |
| EA200870517A1 (ru) | Новые антагонисты мсн-рецепторов | |
| RU2009110442A (ru) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой | |
| JP2009504612A5 (OSRAM) | ||
| ZA200601324B (en) | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | |
| JP2019526571A5 (OSRAM) | ||
| WO2007097197A1 (ja) | アミド誘導体またはその塩 | |
| CN103249414B (zh) | 作为生长激素促泌素受体的生长素释放肽拮抗剂的具有改善受体活性和生物利用度性质的新三唑衍生物 | |
| JP2013540114A5 (OSRAM) | ||
| PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina | |
| JP2017503030A5 (OSRAM) | ||
| JP2014510695A5 (OSRAM) | ||
| JP2009504613A5 (OSRAM) | ||
| JP2017500321A5 (OSRAM) | ||
| JP2009504611A5 (OSRAM) | ||
| US20110237602A1 (en) | Method for treating schizophrenia and related diseases | |
| JP2012522805A5 (OSRAM) | ||
| JP2008534541A5 (OSRAM) | ||
| JP2016536362A5 (OSRAM) | ||
| ES2537093T3 (es) | Derivados de sulfamida utilizados como inhibidores de TAFIa | |
| EP3362058B1 (en) | 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction |